MannKind
Valencia
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $475.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Aug 2025)
- Ticker: nasdaq:MNKD
- Website: mannkindcorp.com
- Phone: (661)775-5300
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/mannkind-59727 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.